Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


“Hot Flash” Persistence At Week 12 Suggests Cool Reception For Products At FDA Cmte

This article was originally published in The Pink Sheet Daily

Executive Summary

Advisory Committee for Reproductive Health Drugs will consider efficacy of Depomed’s and Noven Therapeutics’ vasomotor symptom treatments, but both had problems maintaining their effects at week 12 of clinical trials.


Related Content

First Non-Hormonal Hot Flash Drugs Could Clear FDA Panel In March
Depomed Hot Flash Drug May Finally Be On Its Way To FDA


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts